Biosafety testing of a 293T master cell bank used for production of patient specific lentiviral vectors encoding
Ended Awarded Last action
- Contract number
- HHSN26100018
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77 Part of Sigma-Aldrich Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $127,773
Award facts
- Opportunity
-
- N02RC3600485 Solicitation number
- Biosafety Testing of GMP Master Cell Banks (MCB) and Retroviral Vectors for NCI Clinical Trials Award Notice · Posted Mar 7, 2013
- Contract value 100% obligated
- $127,772.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
About this award
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned, for-profit organization. The contract, valued at $127,772.70, is for biosafety testing of a 293T master cell bank used for production of patient-specific lentiviral vectors encoding. This contract does not have a set-aside designation, indicating Bioreliance's competitive standing in the field of specialized testing services for pharmaceutical and biotechnology research and development. Bioreliance, through its Life Sciences Services Division, has a history of securing federal contracts, particularly from HHS agencies, for services such as endotoxin, sterility, and general safety testing. The parent company of Bioreliance is Sigma-Aldrich Corporation, a leading supplier of laboratory chemicals and related materials, which has primarily served as a subcontractor for federal contracts.
Quick answers
Who was awarded contract HHSN26100018?
HHSN26100018 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on August 17, 2015.
How much is contract HHSN26100018 worth?
The government has obligated $127,773 on HHSN26100018.
Is contract HHSN26100018 an order under another contract?
Yes. HHSN26100018 is a delivery order under HHSN261201300026I, an indefinite delivery contract.
Was contract HHSN26100018 competed?
The extent of competition for HHSN26100018 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award